Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of the three-day event slated to take place Nov. 3-5, 2022, in Miami, Florida. Dr. Kuo will speak on the Mainstream Pharma and Psychedelics panel scheduled for Saturday, Nov. 5, on the Science Main Stage. “It will be an honor to join other industry leaders as a panelist at the most influential conference worldwide for the psychedelic medicine industry,” said Dr. Kuo. “As a sponsor of Wonderland, our company looks forward to building awareness for the exciting work we are doing to advance novel new therapies with the power of psychedelic medicine. Our therapeutics target underserved large disease markets like Alzheimer’s disease, multiple sclerosis, and others that stand to benefit greatly from the breakthrough potential of psychedelic drug treatments.”
To view the full press release, visit https://ibn.fm/Mf3bc
About Silo Pharma Inc.
Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.